Literature DB >> 22338048

Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm.

Danielle M P Cronin1, Tracy I George, Kaaren K Reichard, Uma N Sundram.   

Abstract

Myeloid leukemia cutis (LC) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are morphologically indistinguishable malignancies that frequently manifest in the skin. Separating myeloperoxidase-negative LC from BPDCN may be particularly challenging. We identified a panel of immunohistochemical stains to distinguish myeloid LC (23 cases) from BPDCN (12 cases): myeloperoxidase, which stained 7 cases (30%) of LC and 0 cases (0%) of BPDCN; CD56, which stained 12 cases (52%) of LC and all 12 cases (100%) of BPDCN; CD4, which stained 2 cases (9%) of LC and all 12 cases (100%) of BPDCN; CD123, which stained 4 cases (17%) of LC and 10 cases (83%) of BPDCN; and Tcl-1, which stained 2 cases (9%) of LC and 9 (82%) of 11 cases of BPDCN. It is interesting that CD33 was not helpful; it stained 18 (78%) cases of LC and 11 cases (92%) of BPDCN. Our results indicate that a panel that includes CD4, CD56, CD123, and Tcl-1 can appropriately distinguish between these 2 entities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22338048     DOI: 10.1309/AJCP9IS9KFSVWKGH

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body.

Authors:  Xiao-Bin Cui; Jing Jin; Xue-Lian Pang; Su Li; Chun-Xia Liu; Ting-Ting Li; Hao Peng; Shu-Mao Zhang; Li Li; Wei-Hua Liang; Yun-Zhao Chen; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Authors:  Fabio Facchetti; Stefano Aldo Pileri; Luisa Lorenzi; Valentina Tabanelli; Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-07-10       Impact factor: 4.064

3.  Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.

Authors:  Karen D Wright; Mihaela M Onciu; Elaine Coustan-Smith; Dario Campana; Susana C Raimondi; Hiroto Inaba; Raul Ribeiro; Ching-Hon Pui; John T Sandlund
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

Review 4.  Treatment of blastic plasmacytoid dendritic cell neoplasm.

Authors:  Jill M Sullivan; David A Rizzieri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Blastic plasmacytoid dendritic cell neoplasm with skin and bone marrow involvement: Report of three cases.

Authors:  Jiang-Hong Guo; Hong-Wei Zhang; Li Wang; Wei Bai; Jin-Fen Wang
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

6.  Diagnostic challenges of CD4+/CD56+/CD123+ hematological neoplasms.

Authors:  Leandro S Thiago; Alex Freire Sandes
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

7.  E2-2, a novel immunohistochemical marker for both human and monkey plasmacytoid dendritic cells.

Authors:  Jianping Ma; Haisheng Yu; Xiangyun Yin; Menglan Cheng; Quanxing Shi; Zhao Yin; Xiaohua Nie; Wang Shouli; Liguo Zhang
Journal:  Biophys Rep       Date:  2016-04-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.